Glassman Wealth Services Argenx Se Transaction History

Glassman Wealth Services

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$338.91 - $506.01 $2,033 - $3,036	6 Added 7.06%	91 $34,000
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $1,846 - $2,742	-5 Reduced 5.56%	85 $41,000
Q2 2023 Aug 08, 2023	SELL	$360.14 - $422.58 $720 - $845	-2 Reduced 2.17%	90 $35,000
Q1 2023 May 04, 2023	SELL	$334.23 - $403.65 $3,676 - $4,440	-11 Reduced 10.68%	92 $34,000
Q4 2022 Feb 06, 2023	BUY	$342.17 - $402.31 $4,790 - $5,632	14 Added 15.73%	103 $39,000
Q3 2022 Nov 09, 2022	BUY	$343.2 - $395.75 $2,059 - $2,374	6 Added 7.23%	89 $31,000
Q2 2022 Aug 04, 2022	BUY	$269.58 - $378.88 $9,165 - $12,881	34 Added 69.39%	83 $31,000
Q1 2022 Apr 14, 2022	SELL	$254.45 - $351.06 $1,526 - $2,106	-6 Reduced 10.91%	49 $15,000
Q4 2021 Feb 14, 2022	SELL	$272.01 - $353.03 $816 - $1,059	-3 Reduced 5.17%	55 $19,000
Q3 2021 Nov 10, 2021	SELL	$295.0 - $350.58 $295 - $350	-1 Reduced 1.69%	58 $18,000
Q2 2021 Aug 04, 2021	BUY	$257.11 - $319.92 $514 - $639	2 Added 3.51%	59 $18,000
Q1 2021 May 05, 2021	BUY	$268.3 - $380.31 $2,146 - $3,042	8 Added 16.33%	57 $16,000
Q4 2020 Feb 04, 2021	BUY	$248.13 - $308.36 $12,158 - $15,109	49 New	49 $14,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.